Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit The combination of semaglutide and cagrilintide represents a more advanced approach to fat loss by targeting multiple hormonal pathways involved in appetite, satiety, and glucose regulation. Rather Cagrilintide, Semaglutide (Blend) Liberty Peptides Cagrilintide + Semaglutide Weight Loss Peptides FactorPeptides